Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Aiming for antidepressants
July 2019
SHARING OPTIONS:

TORONTO—A new project is underway that will pursue a novel rapid-acting antidepressant for treating major depressive disorder (MDD). This is the fifth collaboration under MaRS Innovation’s LAB150 partnership with Evotec SE, and includes the Centre for Addiction and Mental Health (CAMH), a MaRS Innovation member organization. The focus of this collaboration will be to develop selective drugs that modulate channels tied to mediating emotional and stress responses, a key focus of the CAMH’s Dr. José Nobrega.
 
“Depression is a leading cause of death and disability around the world,” Nobrega noted. “Identification of new rapid-acting antidepressant treatments could have a major impact on the treatment of depression and the associated risk of suicide. The LAB150 opportunity allows my lab to conduct large-scale drug screening research with our Evotec collaborators, and represents a very significant step towards translating my research into a product of benefit to patients suffering from MDD.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.